Allscripts Healthcare Solutions Inc. (MDRX): Price and Financial Metrics


Allscripts Healthcare Solutions Inc. (MDRX): $17.25

-0.66 (-3.69%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

MDRX POWR Grades

  • Quality is the dimension where MDRX ranks best; there it ranks ahead of 79.99% of US stocks.
  • MDRX's strongest trending metric is Value; it's been moving down over the last 179 days.
  • MDRX's current lowest rank is in the Sentiment metric (where it is better than 8.77% of US stocks).

MDRX Stock Summary

  • With a year-over-year growth in debt of -52.38%, VERADIGM INC's debt growth rate surpasses just 5.04% of about US stocks.
  • As for revenue growth, note that MDRX's revenue has grown -39.73% over the past 12 months; that beats the revenue growth of merely 4.93% of US companies in our set.
  • VERADIGM INC's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is 24.95%, greater than the shareholder yield of 94.38% of stocks in our set.
  • If you're looking for stocks that are quantitatively similar to VERADIGM INC, a group of peers worth examining would be VIAV, NATI, ATEN, CMBM, and IBIO.
  • MDRX's SEC filings can be seen here. And to visit VERADIGM INC's official web site, go to www.allscripts.com.

MDRX Valuation Summary

  • In comparison to the median Technology stock, MDRX's price/sales ratio is 14.81% lower, now standing at 2.3.
  • Over the past 243 months, MDRX's price/sales ratio has gone up 1.3.

Below are key valuation metrics over time for MDRX.

Stock Date P/S P/B P/E EV/EBIT
MDRX 2023-01-27 2.3 1.6 32.0 21.3
MDRX 2023-01-26 2.4 1.7 32.6 21.7
MDRX 2023-01-25 2.4 1.7 32.5 21.7
MDRX 2023-01-24 2.4 1.7 32.5 21.7
MDRX 2023-01-23 2.4 1.7 33.2 22.3
MDRX 2023-01-20 2.4 1.7 33.3 22.4

MDRX Growth Metrics

    Its 5 year price growth rate is now at -48.3%.
  • The 3 year revenue growth rate now stands at -23.42%.
  • Its 3 year net income to common stockholders growth rate is now at -55.79%.
Over the past 67 months, MDRX's revenue has gone down $780,625,000.

The table below shows MDRX's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 837.191 160.811 60.634
2022-06-30 1,054.541 188.56 62.286
2022-03-31 1,277.357 -10.742 148.238
2021-12-31 1,503.037 -75.428 134.438
2021-09-30 1,389.072 -319.092 774.987
2021-06-30 1,421.83 -322.015 759.349

MDRX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • MDRX has a Quality Grade of C, ranking ahead of 38.48% of graded US stocks.
  • MDRX's asset turnover comes in at 0.496 -- ranking 62nd of 83 Computers stocks.
  • INVE, CLSK, and DGII are the stocks whose asset turnover ratios are most correlated with MDRX.

The table below shows MDRX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.496 0.384 1.040
2021-03-31 0.480 0.384 0.931
2020-12-31 0.481 0.376 0.725
2020-09-30 0.524 0.396 -0.018
2020-06-30 0.534 0.394 -0.025
2020-03-31 0.544 0.397 -0.172

MDRX Price Target

For more insight on analysts targets of MDRX, see our MDRX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $17.86 Average Broker Recommendation 1.79 (Moderate Buy)

MDRX Stock Price Chart Interactive Chart >

Price chart for MDRX

MDRX Price/Volume Stats

Current price $17.25 52-week high $23.25
Prev. close $17.91 52-week low $13.59
Day low $17.25 Volume 204,202
Day high $17.59 Avg. volume 1,169,191
50-day MA $18.21 Dividend yield N/A
200-day MA $17.02 Market Cap 1.88B

Allscripts Healthcare Solutions Inc. (MDRX) Company Bio


AllScripts Healthcare Solutions provides clinical, financial, electronic health records (EHR), connectivity, hosting, outsourcing, analytics, patient engagement, and population health products and services in the United States and Canada. It operates in three segments: Clinical and Financial Solutions, Population Health, and Managed Services. The company was founded in 1986 and is based in Chicago, Illinois.


MDRX Latest News Stream


Event/Time News Detail
Loading, please wait...

MDRX Latest Social Stream


Loading social stream, please wait...

View Full MDRX Social Stream

Latest MDRX News From Around the Web

Below are the latest news stories about VERADIGM INC that investors may wish to consider to help them evaluate MDRX as an investment opportunity.

Sector Spotlight: HealthCare Software Stocks For 2023

Companies that develop and market software solutions for the healthcare sector are referred to as "medical management software stocks." Electronic health records (EHRs), practice management systems...

Yahoo | January 17, 2023

Veradigm Takes Action with FY23 Outlook and Major Share Buyback Initiative

Veradigm Inc (NASDAQ: MDRX) shares are trading higher Wednesday after the company announced a new share repurchase program under which Veradigm may purchase up to $250 million of its common stock. The new share repurchase program does not have a termination date and replaces the previous authorization to repurchase $250 million of common stock, which was almost fully utilized in 2022. In the fourth quarter of 2022, Veradigm repurchased $57 million of its common stock, bringing its full-year tota

Yahoo | January 11, 2023

Veradigm Announces New Share Repurchase Program and Initial Financial Guidance for Fiscal 2023

CHICAGO, January 11, 2023--Veradigm Inc. (NASDAQ: MDRX), formerly Allscripts Healthcare Solutions, Inc., announced today that its Board of Directors has approved a new share repurchase program under which Veradigm may purchase up to $250 million of its common stock. The new share repurchase program does not have a termination date and replaces the previous authorization to repurchase $250 million of common stock which was almost fully utilized during 2022. In the fourth quarter of 2022 Veradigm

Yahoo | January 11, 2023

Veradigm Building Momentum Across All Markets

CHICAGO, January 10, 2023--Veradigm Inc. (NASDAQ: MDRX) reports today strong fourth quarter new business results across all markets including the payer, life science, and provider markets.

Yahoo | January 10, 2023

Veradigm Announces Strategic Investment in Holmusk

CHICAGO, January 09, 2023--Veradigm Inc. (NASDAQ: MDRX), formerly Allscripts Healthcare Solutions, Inc., announced today an investment in Holmusk, a global behavioral health real-world evidence and data analytics company, as part of Holmusk’s $45 million series B financing round. The round was led by Veradigm, with participation from current investors including Heritas Capital, Health Catalyst Capital, Novartis (dRx Capital), and Northwell Holdings, the venture investment arm of Northwell Health

Yahoo | January 9, 2023

Read More 'MDRX' Stories Here

MDRX Price Returns

1-mo N/A
3-mo 24.10%
6-mo -1.60%
1-year -17.11%
3-year 101.05%
5-year 18.88%
YTD -2.21%
2022 -4.39%
2021 27.77%
2020 47.12%
2019 1.82%
2018 -33.75%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7829 seconds.